icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
29 Apr, 2010 06:55

Pharmstandard posts FY 2009 net profit of 6.85 billion roubles

Pharmstandard posts FY 2009 net profit of 6.85 billion roubles

Russian pharmaceutical drug producer, Pharmstandard, has posted a FY 2009 net profit of 6.852 billion roubles under IFRS.

The bottom line was up 96% year on year with FY 2009 EBITDA rising 59% to 9.41 billion roubles, as revenues climbed 68% to 24.095 billion roubles.

The company said the results were boosted by strong Arbidol sales, with a spike in purchasing stemming from widespread concerns about swine and bird influenza, and the drug widely believed to be effective against these. More broadly, Pharmstandard noted a 77% increase in pharmaceutical product sales, with a 36% decline in sales of medical equipment and disposables.

In an accompanying statement Pharmstandard also indicated that 1Q 2010 sales were up 25% to 5.727 billion roubles.